Utilizing a CCR2 blocker, PF-04136309, within an orthotopic mouse model of pancreatic cancer demonstrated the ability to decelerate tumor growth and metastasis by diminishing MDSC infiltration in tumor tissues via the CCL2/CCR2 pathway (208). Here, CCR2 is linked to pancreatic neoplasm.